These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24373724)

  • 21. Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
    Codony S; Valverde E; Leiva R; Brea J; Isabel Loza M; Morisseau C; Hammock BD; Vázquez S
    Bioorg Med Chem; 2019 Oct; 27(20):115078. PubMed ID: 31488357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Orally bioavailable potent soluble epoxide hydrolase inhibitors.
    Hwang SH; Tsai HJ; Liu JY; Morisseau C; Hammock BD
    J Med Chem; 2007 Aug; 50(16):3825-40. PubMed ID: 17616115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacophoric modeling and atom-based 3D-QSAR of novel 1-aryl-3-(1-acylpiperidin-4-yl) urea as human soluble epoxide hydrolase inhibitors (sEHIs).
    Das N; Dhanawat M; Kulshrestha A; Shrivastava SK
    Med Chem; 2011 Nov; 7(6):581-92. PubMed ID: 22313298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties.
    Kim IH; Tsai HJ; Nishi K; Kasagami T; Morisseau C; Hammock BD
    J Med Chem; 2007 Oct; 50(21):5217-26. PubMed ID: 17894481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Occurrence of urea-based soluble epoxide hydrolase inhibitors from the plants in the order Brassicales.
    Kitamura S; Morisseau C; Harris TR; Inceoglu B; Hammock BD
    PLoS One; 2017; 12(5):e0176571. PubMed ID: 28472063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
    Kim IH; Heirtzler FR; Morisseau C; Nishi K; Tsai HJ; Hammock BD
    J Med Chem; 2005 May; 48(10):3621-9. PubMed ID: 15887969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition.
    Davis BB; Morisseau C; Newman JW; Pedersen TL; Hammock BD; Weiss RH
    J Pharmacol Exp Ther; 2006 Feb; 316(2):815-21. PubMed ID: 16221742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis.
    Du F; Sun W; Morisseau C; Hammock BD; Bao X; Liu Q; Wang C; Zhang T; Yang H; Zhou J; Xiao W; Liu Z; Chen G
    Eur J Med Chem; 2021 Nov; 223():113678. PubMed ID: 34218083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of phthalimide derivatives as novel inhibitors of a soluble epoxide hydrolase.
    Mahlooji I; Shokri M; Manoochehri R; Mahboubi-Rabbani M; Rezaee E; Tabatabai SA
    Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000052. PubMed ID: 32484272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent urea and carbamate inhibitors of soluble epoxide hydrolases.
    Morisseau C; Goodrow MH; Dowdy D; Zheng J; Greene JF; Sanborn JR; Hammock BD
    Proc Natl Acad Sci U S A; 1999 Aug; 96(16):8849-54. PubMed ID: 10430859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro metabolism of the mammalian soluble epoxide hydrolase inhibitor, 1-cyclohexyl-3-dodecyl-urea.
    Watanabe T; Morisseau C; Newman JW; Hammock BD
    Drug Metab Dispos; 2003 Jul; 31(7):846-53. PubMed ID: 12814960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors:
    Codony S; Pujol E; Pizarro J; Feixas F; Valverde E; Loza MI; Brea JM; Saez E; Oyarzabal J; Pineda-Lucena A; Pérez B; Pérez C; Rodríguez-Franco MI; Leiva R; Osuna S; Morisseau C; Hammock BD; Vázquez-Carrera M; Vázquez S
    J Med Chem; 2020 Sep; 63(17):9237-9257. PubMed ID: 32787085
    [No Abstract]   [Full Text] [Related]  

  • 33. Discovery of benzamide derivatives containing urea moiety as soluble epoxide hydrolase inhibitors.
    Tian Y; Li S; Dong K; Su X; Fu S; Lv X; Duan M; Yang T; Han Y; Hu G; Liu J; Sun Y; Yue H; Sun Y; Zhang H; Du Z; Miao Z; Tong M; Liu Y; Qin M; Gong P; Hou Y; Gao Z; Zhao Y
    Bioorg Chem; 2022 Oct; 127():105898. PubMed ID: 35792317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase.
    Pecic S; Deng SX; Morisseau C; Hammock BD; Landry DW
    Bioorg Med Chem Lett; 2012 Jan; 22(1):601-5. PubMed ID: 22079754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.
    Yang H; Lin XF; Padilla F; Gabriel SD; Heilek G; Ji C; Sankuratri S; deRosier A; Berry P; Rotstein DM
    Bioorg Med Chem Lett; 2009 Jan; 19(1):209-13. PubMed ID: 19014885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imidazolidine-2,4,5- and pirimidine-2,4,6-triones - New primary pharmacophore for soluble epoxide hydrolase inhibitors with enhanced water solubility.
    Burmistrov V; Morisseau C; D'yachenko V; Karlov D; Butov GM; Hammock BD
    Bioorg Med Chem Lett; 2020 Feb; 30(3):126908. PubMed ID: 31870649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors.
    Shen HC; Ding FX; Deng Q; Xu S; Tong X; Zhang X; Chen Y; Zhou G; Pai LY; Alonso-Galicia M; Roy S; Zhang B; Tata JR; Berger JP; Colletti SL
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5716-21. PubMed ID: 19700315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitors.
    Hwang SH; Morisseau C; Do Z; Hammock BD
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5773-7. PubMed ID: 16949285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
    Mehrotra MM; Heath JA; Smyth MS; Pandey A; Rose JW; Seroogy JM; Volkots DL; Nannizzi-Alaimo L; Park GL; Lambing JL; Hollenbach SJ; Scarborough RM
    J Med Chem; 2004 Apr; 47(8):2037-61. PubMed ID: 15056002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioisosteric substitution of adamantane with bicyclic lipophilic groups improves water solubility of human soluble epoxide hydrolase inhibitors.
    Burmistrov V; Morisseau C; Karlov D; Pitushkin D; Vernigora A; Rasskazova E; Butov GM; Hammock BD
    Bioorg Med Chem Lett; 2020 Sep; 30(18):127430. PubMed ID: 32736212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.